Study of EGF816 in combination with selected targeted agents in EGFR-mutant NSCLC.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511757-21-00

Acronym

CEGF816X2102

Enrollment

Registered

2024-07-05

Start date

2024-12-20

Completion date

Unknown

Last updated

2025-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with EGFR-mutant Non Small Cell Lung Cancer

None listed

Sex/Gender

All

Age

18 Years to No maximum

Germany, Italy

None listed

Source: EU CTIS · Data processed: Feb 4, 2026